FDA Seeks Input On How To Identify, Measure Disease Symptoms Most Meaningful For Patients

FDA will host a two-day patient-focused drug development meeting in October in a bid to better understand how to identify what is most important to patients and caregivers with regard to burdens associated with diseases and disease treatment; benefits and risks when managing a patient’s disease; and using fit-for-purpose clinical outcome assessments (COAs) to measure patient experience in clinical trials, the agency announced Friday (Aug. 10). The meeting, which will be held Oct. 15 and 16, fulfills FDA’s requirements under...